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O B J E C T I V E S This study sought to evaluate the relationship between microalbuminuria (MA) and
the development and progression of atherosclerosis, as assessed by incident and progression of
coronary artery calciﬁcation (CAC).
B A C KG ROUND MA is associated with an increased risk of cardiovascular disease, but the
mechanism by which MA imparts this increased risk is not known.
METHOD S TheMESA (Multi-Ethnic Study of Atherosclerosis) study is a prospective cohort study of 6,814
self-identiﬁed White, African-American, Hispanic, or Chinese participants free of clinical cardiovascular disease at
entry. Of the 6,775 individuals with available urine albumin data, we excluded 97 subjects with macroalbuminuria
and 1,023 with missing follow-up CAC data. The ﬁnal study population consists of 5,666 subjects.
R E S U L T S At baseline, individuals with MA were more likely to have CAC 0 compared with those
without MA (62% vs. 48%, p  0.0001). During a mean follow-up of 2.4  0.8 years, those with MA and
no CAC at baseline were more likely to develop CAC (relative risk [RR]: 2.05, 95% conﬁdence interval [CI]:
1.41 to 3.02, p  0.0001) as compared with those without MA in demographic-adjusted analyses. After
multivariant adjustment, the relationship was attenuated but remained statistically signiﬁcant (RR: 1.76,
95% CI: 1.19 to 2.61, p 0.005). Among those with CAC at baseline, those with versus those without MA
had a 15 (95% CI: 8 to 22, p  0.0001) volume units higher median increase in CAC in demographic-
adjusted analyses. After multivariant adjustment, MA remained associated with incident CAC (RR: 1.76,
95% CI: 1.19 to 2.61, p  0.005) and with progression of CAC (median increase in CAC volume score of
9 [95% CI: 2 to 16, p  0.009]), relative to those without MA.
CONC L U S I O N S This large multiethnic, population-based study of asymptomatic individuals demon-
strates an increased risk of incident CAC as well as greater CAC progression among those with MA. Further
study is needed to determine the degree to which MA precedes and predicts progression of atherosclerosis
and how this information can be used to reduce cardiovascular events. (J Am Coll Cardiol Img 2010;3:
595–604) © 2010 by the American College of Cardiology Foundation
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596nalysis of cohort studies including more than
15,000 participants have demonstrated a pro-
gressive increase in cardiovascular events with
increasing urine albumin excretion in dia-
etic, nondiabetic, symptomatic, and asymptomatic
ndividuals (1–3). Additionally, a reduction in urine
lbumin excretion at 1 year was associated with a
eduction in the risk of the composite end point of
ardiovascular death, myocardial infarction, or stroke
n 8,206 subjects treated with antihypertensive medi-
ations (4).
The mechanism by which increased urine albumin
xcretion contributes to cardiovascular risk is not
ntirely clear. Studies have demonstrated that various
easures of endothelial function correlate with mi-
roalbuminuria (MA) (defined as excretion of 30 to
00 mg albumin/day) in older adults and diabetic
atients (5–7). Recently, Kramer et al. have demon-
trated that the presence of MA is associated with a
igher burden of coronary artery calcification (CAC)
in the MESA (Multi-Ethnic Study of Ath-
erosclerosis) study (8). However, data on
whether MA is associated with progression
of atherosclerosis are sparse.
CAC is a measure of atherosclerosis
that has been shown to predict future
cardiovascular events in multiple asymp-
tomatic populations (9–18), and limited
data suggest that progression of CAC may
predict future cardiovascular disease risk
with greater accuracy than a single mea-
sure of CAC (19,20).
The MESA study provides a unique op-
ortunity to study the association of increasing degree
f urine albumin excretion with progression of CAC
n a large, gender-balanced asymptomatic cohort (21).
e hypothesized that asymptomatic individuals with
A would have higher degrees of CAC progression
nd that this relationship will be independent of other
oronary heart disease (CHD) risk factors. Establish-
ng a relationship between MA and CAC progression
ould add to our understanding of how MA contrib-
tes to cardiovascular risk. It would support the
ypothesis that MA is a global measure of vascular
ealth (22)—that is, a summation measure of the
mpact that known and/or unknown vascular insults
hypertension, dyslipidemia, smoking, etc.) have on an
ndividual’s vasculature.
E T H O D S
ESA is a prospective epidemiologic study of the
se
einrevalence, risk factors, and progression of subclin- pcal cardiovascular disease in a multiethnic cohort.
he study design and methods has been previously
ublished (21). Briefly, 6,814 participants aged 45
o 84 years who identified themselves as White,
frican American, Hispanic, or Chinese were re-
ruited from 6 U.S. communities (Forsyth County,
orth Carolina; Northern Manhattan and the
ronx, New York; Baltimore City and Baltimore
ounty, Maryland; St. Paul, Minnesota; Chicago,
llinois; and Los Angeles County, California) in
000 to 2002. These participants were free of
linical cardiovascular disease (myocardial infarc-
ion, angina, stroke, transient ischemic attack, heart
ailure, atrial fibrillation, revascularization, valve
eplacement, pacemaker or defibrillator implanta-
ion, or taking nitroglycerin).
An approximately equal number of men and
omen were recruited according to pre-specified
ge and race/ethnicity strata. All participants gave
nformed consent, and the study protocol was ap-
roved by the institutional review board at each site.
Medical history, anthropometric measurements,
nd laboratory data for the present study were taken
rom the first examination of the MESA cohort
July 2000 to August 2002) as previously described
21). Urine albumin and creatinine were measured
t the Clinical Chemistry Laboratory at Fletcher
llen Health Care (Burlington, Vermont). Urine
lbumin and creatinine were measured by nephe-
ometry and the rate Jaffe reaction, respectively.
pot urine albumin (g/ml)-to-creatinine (mg/ml)
atios (UACRs) were calculated for all participants
xcept those with missing urine data (n  39).
articipants were classified as those with MA (30 to
00 mg albumin/g creatinine) and those with nor-
al UACR (30 mg/g). This study does not
valuate the relationship between chronic kidney
isease and CAC, and therefore, those with mac-
oalbuminuria, UACR 300 mg/g, were excluded
rom the study.
easurement of CAC. CAC was measured using
ither electron-beam tomography (EBT) (3 sites)
r multidetector computed tomography (MDCT)
3 sites). Participants were scanned twice consecu-
ively, and each scan was read by a single trained
hysician-reader independently at a centralized
eading center (Harbor-UCLA Medical Center/
os Angeles Biomedical Research Institute, Tor-
ance, California). The methodology for acquisition
nd interpretation of the scans, as well as reproduc-
bility of the readings, has been reported previously
23). The results from the 2 scans were averaged toB B R E V I A T I O N S
N D A C R O N YM S
AC coronary artery
alcification
HD coronary heart disea
BT electron-beam
omography
DL high-density lipoprot
Amicroalbuminuria
ACR urine albumin-to-rovide a more accurate point estimate of the
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597mount of calcium present. Calcium scores were
djusted using a standard calcium phantom that was
canned along with the participant. The phantom
ontained 4 bars of known calcium density, and was
sed to calibrate the X-ray attenuation level be-
ween measurements conducted on different ma-
hines (24). Any detectable calcium was defined as
n Agatston CAC score greater than 0 (25); a
inimum focus of calcification was based on at least
contiguous voxels, which resulted in identification
f calcium of 1.15 mm3 for the MDCT scanners
nd 1.38 mm3 for the EBT scanners. The nominal
ection thickness was 3.0 mm for EBT scanners and
.5 mm for MDCT.
To quantify CAC progression, a second CAC
easurement was performed on one-half of the
ohort (randomly selected) at a second exam (Sep-
ember 2002 to January 2004) and on the other half
f the cohort at a third exam (March 2004 to July
005), an average of 1.6 and 3.2 years after the first
can, respectively (overall average time between
cans of 2.4 years). The distribution of CAC in
ESA at baseline by age, gender, and race has been
ublished previously (26).
tatistical analysis. All participants with both a base-
ine and a follow-up CAC measurement were
ncluded in the analysis. The presence of CAC was
efined as an Agatston score 0. Progression of
AC was defined in 2 ways as previously described
y Kronmal et al. (27); incident CAC defined as
etectable CAC at the follow-up examination (ei-
her examination 2 or 3) in a participant free of
etectable CAC at examination 1; and change in
AC volume score in participants who had detect-
ble CAC at examination 1.
The association of incident CAC and median
ncrease in CAC volume with presence of MA as
ell as increasing UACR as a continuous variable
natural logarithmic transformation) was assessed.
elative risk regression was used to model the
robability of incident-detectable CAC among
hose free of CAC at examination 1. The probabil-
ty of incident CAC was modeled as a function of
ovariates using a generalized linear model with log
ink and binomial error distribution. Relative risk
egression was used rather than logistic regression
ecause the incidence of new calcification was
10%, so the odds ratio is an overestimate of the
elative risk. To estimate the progression of CAC
mong those with detectable CAC at baseline, we
sed median regression analyses. These 2 end
oints were modeled separately and stratified on
ace/ethnicity. Risk factors considered include age, iender, MESA site, follow-up duration, body mass
ndex (height/meter2), hypertension, diabetes mel-
itus, cigarette smoking, family history of CHD,
holesterol levels, and use of cholesterol-lowering
edications.
Two sets of multivariable models were examined
n a hierarchical fashion: 1) adjusted for age, gender,
ace, MESA site, and duration of follow-up; and
) adjusted for age, gender, race, MESA site,
ollow-up duration, body mass index, hypertension,
iabetes mellitus, cigarette smoking, family history
f CHD, low-density lipoprotein (LDL), high-
ensity lipoprotein (HDL), triglycerides, and
holesterol-lowering medications. Baseline CAC
as not included in our multivariant analysis be-
ause inclusion would lead to overcorrection/
vermodeling because the factors that produce
aseline CAC are certainly contributory to CAC
rogression. Effect modification by scan type, sys-
olic blood pressure as a continuous variable, creat-
nine level, and estimated glomerular filtration rate
Cockroft and Gault equation) was evaluated. Race
as not adjusted for race-specific analyses. An
nteraction term with MA and race/ethnicity was
reated to assess for interaction.
We used chi-square tests for categorical variables
nd t test for continuous variables to test for
ifferences between participants with and without
A to assess for baseline differences in demograph-
cs and cardiovascular risk factors.
All statistical analyses were completed using
TATA software version 8 (College Station,
exas).
E S U L T S
he current study included the 6,775 individuals
hat had data available on UACR. We excluded 97
ubjects with macroalbuminuria; in addition, 1,023
ith missing follow-up computed tomography were
ot considered in the final study analysis. The final
tudy population consists of 5,666 MESA partici-
ants (mean age 62  10 years; 48% males).
verall, 424 (7%) individuals had UACR in the
ange of 30 to 300 mg/g (with MA) (Fig. 1).
Table 1 describes the baseline characteristics
etween those with and without MA (UACR 30
g/g). Whites were less likely to have MA than
hinese, African-American, and Hispanic study
articipants. Those with MA were older and more
ikely to have hypertension, diabetes mellitus,
igher triglycerides, lower HDL, higher body massndex, more likely to be on cholesterol-lowering
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598edications, have a higher serum creatinine and
ower estimate glomerular filtration rate but less
ikely to have a family history of heart attack than
hose without MA (Table 1).
At baseline, individuals with MA were more
ikely to have CAC 0 compared with those with
ormal UACR (62% vs. 48%, p  0.0001) (Fig. 1).
n addition, among those with CAC, both volume
core and Agatston score were higher in those with
A (p  0.01). Among the 2,911 participants
51%) without detectable CAC at baseline, 462
16%) went on to develop incident CAC over an
verage of 2.4  0.8 years of follow-up. The
ncidence of CAC (per 100 person-years) was
ignificantly higher among those with MA; this
eature was observed in all racial/ethnic groups
Figs. 1 and 2).
The relative risks for incident CAC (among
hose without CAC at baseline) was elevated for
hose with MA and those with increasing levels of
og-transformed UACR (Tables 2 and 3). In our
tudy, compared with participants with UACR
30 mg/g, those with MA had a higher risk of
ncident CAC (relative risk [RR]: 2.05, 95% con-
dence interval [CI]: 1.41 to 3.02, p  0.0001) in
he analysis adjusted for demographic factors and
ite (model 1). After further adjustment for CHD
Final Stud
5,666
MA (+) UACR >300 mg/g
424 (7%)
CAC (+) Baseline
262 (62%)
Baseline Median
CAC Score 96
CAC (–) Baseline
162 (38%)
Incident CAC at
Follow-up Exam
46 (28%)
Median CAC
Change +47
Figure 1. Study Population Subgroups According to Baseline M
This ﬁgure illustrates the breakdown of those with versus those wit
cium (CAC) was identiﬁed in these subjects, the percentage of subj
the median increase in CAC among those with CAC at baseline. At
with MA (62%) versus those without MA (48%). A greater likelihood
versus those without (15%) MA, and a greater median progression
without MA (28) were identiﬁed.isk factors, the relationship was somewhat attenu- (ted but remained statistically significant (RR: 1.76,
5% CI: 1.19 to 2.61, p  0.005). As shown in
able 3, continuous UACR (log-transformed) was
lso significantly associated with incident CAC,
ith a relative risk ratio of 1.15 (95% CI: 1.03 to
.30). In analyses stratified by ethnicity, the relative
isk of incident CAC was not consistently greater
y MA and increasing levels of UACR (log-
ransformed) among any of the ethnic groups stud-
ed (Tables 2 and 3), and no interaction between
ace and MA for incident CAC was detected (data
ot shown). However, a significant interaction was
resent for an increased risk of incident CAC with
ncreasing levels of UACR (log-transformed)
mong Chinese as compared with Whites (p 
.02). Adjustment for type of scanner used to access
AC, systolic blood pressure as a continuous vari-
ble, creatinine, or estimate glomerular filtration
ate had no significant impact on the results.
Among those with CAC at baseline, the median
bsolute progression of CAC was significantly
igher by presence of MA (Figs. 1 and 3). The
bsolute median CAC increase in those with and
ithout MA was 47 and 28, respectively (p 
.0001). From median regression analyses (Table 4),
edian progression among those with MA was
5.0 (95% CI: 8.1 to 21.9, p 0.0001) units higher
pulation
0%)
MA (–) UACR 30-300 mg/g
5,242 (93%)
CAC (+) Baseline
2,493 (48%)
Baseline Median
CAC Score 96
CAC (–) Baseline
2,749 (52%)
Incident CAC at
Follow-up Exam
416 (15%)
Median CAC
Change +28
d CAC as Well as Follow-Up CAC Progression
t microalbuminuria (MA) at baseline, whether coronary artery cal-
without CAC at baseline who developed CAC on follow-up, and
line, a greater percentage of CAC was identiﬁed among those
developing incident CAC at follow-up among those with (28%)
AC among those with CAC at baseline and MA (47) versus thosey Po
 (10
A an
hou
ects
base
of
of Cvolume) than those without MA in demographic-
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599djusted analyses; the respective change was re-
uced to 9.4 units (95% CI: 2.3 to 16.5, p  0.009)
n the fully adjusted analyses (model 2). Although
he association between median increase in coro-
ary calcium volume and MA/log-transformed
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s
0
4
2
8
6
12
16
10
14
Overall
6
11
White
7
11
Microalbuminuria
Figure 2. Incident CAC per 100 Person-Years According to MA a
Overall, those with baseline microalbuminuria (MA) (solid bars) had
those without MA (open bars). In this univariant analysis, stratiﬁed
Table 1. Baseline Characteristics of Study Population
U
Age (years)
Gender (male)
Race
Whites
Chinese
African Americans
Hispanics
Current smoker
Hypertension
Systolic blood pressure (mm Hg)
Diabetes mellitus
Family history of heart attack
LDL-C (mg/dl)
Triglycerides (mg/dl)*
HDL-C (mg/dl)
BMI (kg/m2)
Lipid-lowering meds
Creatinine
Estimated GFR (Cockroft and Gault)
CAC 0
Baseline volume score (among those with CAC 0)*
Baseline Agatston score (among those with CAC 0)*
*Tests for association done on the mean of log-transformed data.
BMI  body mass index; CAC  coronary artery calciﬁcation; GFR  glomerula
lipoprotein cholesterol.with versus those without MA persisted.ACR remained statistically significant only in
frican-American participants in the fully adjusted
odel (Table 4 and 5). However, no interaction
etween race and MA or UACR (log-transformed)
or progression of CAC was detected (data not
inese
15
African
American
6
14
Hispanic
6
9
Microalbuminuria (+)
Stratiﬁed by Race/Ethnicity
ater incident coronary artery calcium (CAC) as compared with
elf-identiﬁed race, the trend of greater incident CAC among those
R <30 mg/g
 5,242)
Microalbuminuria
(n  424) p Value
62 10 67 10 0.0001
47% 51% 0.12
94% 6%
90% 10% 0.0001
90% 10%
90% 10%
13% 13% 0.825
42% 74% 0.0001
25 20 140 23 0.0001
11% 37% 0.0001
43% 38% 0.017
17 31 115 34 0.07
28 77 158 154 0.0001
51 15 48 13 0.0001
28 5 30 6 0.0001
16% 20% 0.0001
.94 0.20 1.00 0.32 0.0001
87 27 83 34 0.02
48% 62% 0.0001
66 488 384 674 0.0001
34 407 339 562 0.0001
ration rate; HDL-C  high-density lipoprotein cholesterol; LDL-C  low-densityCh
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600hown). Adjustment for type of scanner used to
ccess CAC, systolic blood pressure as a continuous
ariable, creatinine, or estimate glomerular filtration
ate had no significant impact on the results.
I S C U S S I O N
he present study examined the association be-
ween MA and development of CAC as well as
rogression of CAC in a large, community-based
ample of asymptomatic individuals. MA is associ-
ted with cardiovascular events and appears to be a
easure of vascular health (22). Our finding ex-
ends these observations by demonstrating that in
ndividuals free of CHD, MA is associated with a
reater incidence and degree of progression of CAC
ompared with those without MA, independent of
raditional CHD risk factors, creatinine, or estimate
lomerular filtration rate.
MA has been independently associated with
ultiple markers of subclinical atherosclerosis, in-
luding left ventricular hypertrophy, carotid artery
all intima–media thickness, pulse wave velocity,
arotid plaque number, and carotid and coronary
rtery calcium (28–30). Additionally, we have pre-
iously demonstrated an association between MA
Table 2. RRR (95% CI) of Incident CAC With Presence of MA
MA (Baseline) Incident CAC
Overall (n  2,911) 162 (6%) 462 (16%)
Whites (n  1,001) 23 (2%) 176 (18%)
Chinese Americans (n  348) 24 (7%) 39 (11%)
African Americans (n  899) 68 (7%) 142 (16%)
Hispanics (n  663) 47 (7%) 105 (16%)
Model adjusted for age, gender, race, *MESA site, and follow-up duration. Mode
hypertension, diabetes mellitus, cigarette smoking, family history of CHD, LDL
scanner used to access CAC, systolic blood pressure as a continuous variable,
results. *Race was not adjusted for race-speciﬁc analyses.
CHD  coronary heart disease; CI  conﬁdence interval; MA  microalbumin
abbreviations as in Table 1.
Table 3. RRR (95% CI) of Incident CAC With Increasing Levels o
MA (Baseline) Incident CAC
Overall (n  2,911) 162 (6%) 462 (16%)
Whites (n  1,001) 23 (2%) 176 (18%)
Chinese Americans (n  348) 24 (7%) 39 (11%)
African Americans (n  899) 68 (7%) 142 (16%)
Hispanics (n  663) 47 (7%) 105 (16%)
Model 1 adjusted for age, gender, race, *MESA site, and follow-up duration. Mod
hypertension, diabetes mellitus, cigarette smoking, family history of CHD, LDL
scanner used to access CAC, systolic blood pressure as a continuous variable,
results. *Race was not adjusted for race-speciﬁc analyses.
UACR  spot urine albumin-to-creatinine ratio; other abbreviations as in Tables 1nd CAC in the MESA population (8). However,
nly scant data exist regarding the influence of MA
n the progression of subclinical atherosclerosis.
he Tromoso study, a prospective study of 4,037
ubjects without diabetes who were followed for an
verage of 7 years, demonstrated a positive relation-
hip between baseline MA and the incidence and
rogression of plaque (size and number) in the
arotid arteries using ultrasonography (31). After
ontrolling for traditional cardiovascular disease risk
actors, MA was also associated with both the
umber of new plaques and the total plaque area at
ollow-up among 2,203 subjects without any iden-
ifiable carotid plaque at baseline. The PREDICT
The Progress of Coronary Heart Disease in Type 2
iabetes as Measured by Coronary Calcium Score
rom Electron Beam Computed Tomography)
tudy (32) evaluated 202 type 2 diabetic patients
ithout known clinical cardiovascular disease with
equential CAC scans. After a mean follow-up of 4
ears, UACR was positively associated with CAC
rogression after controlling for baseline CAC
core (32). Costacou et al. (33) demonstrated a
ositive association between MA and CAC pro-
ression in a study of 222 type 1 diabetics with
Model 1 Model 2
RRR (95% CI) p Value RRR (95% CI) p Value
2.05 (1.41–3.02) 0.0001 1.76 (1.19–2.61) 0.005
1.36 (0.50–3.67) 0.55 1.09 (0.37–3.19) 0.87
4.08 (1.61–10.37) 0.0001 2.77 (0.96–7.9) 0.059
2.43 (1.37–4.36) 0.003 2.22 (1.22–4.03) 0.009
1.48 (0.70–3.14) 0.31 1.16 (0.51–2.61) 0.72
djusted for age, gender, race, *MESA site, follow-up duration, body mass index,
L, triglycerides, and cholesterol-lowering medications. Adjustment for type of
inine, or estimated glomerular ﬁltration rate had no signiﬁcant impact on the
MESA  Multi-Ethnic Study of Atherosclerosis; RRR  relative risk ratio; other
CR (Log-Transformed)
)
Model 1 Model 2
RRR (95% CI) p Value RRR (95% CI) p Value
1.24 (1.11–1.38) 0.0001 1.15 (1.03–1.30) 0.016
1.09 (0.87–1.37) 0.43 1.00 (0.80–1.26) 0.97
1.62 (1.19–2.21) 0.002 1.45 (1.02–2.05) 0.038
1.24 (1.04–1.47) 0.019 1.16 (0.96–1.41) 0.13
1.25 (1.01–1.56) 0.039 1.17 (0.91–1.51) 0.23
djusted for age, gender, race, *MESA site, follow-up duration, body mass index,
L, triglycerides, and cholesterol-lowering medications. Adjustment for type of
inine, or estimated glomerular ﬁltration rate had no signiﬁcant impact on the(FU)
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601AC scans at baseline and 4 years later. This
elationship remained significant after controlling
or baseline CAC, duration of diabetes diagnosis,
ody mass index, and non-HDL cholesterol. Insu-
in dose, hypertension, systolic blood pressure,
hite blood cell count, and angiotensin-converting
nzyme inhibitor use did not impact model fit, and
esults were unchanged when restricted to the 183
atients free of clinically recognized cardiovascular
isease.
Our study results are consistent with the findings
rom the studies highlighted in the previous text
nd add to current literature by demonstrating that
A is associated with incident CAC and CAC
rogression among low-risk individuals with and
ithout detectable CAC at baseline. Among those
ith CAC  0 at baseline, we observed nearly a
-fold increased incidence of CAC among those
ith MA. These associations were attenuated but
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Figure 3. Median CAC Change According to MA and Stratiﬁed b
Overall, those with baseline coronary artery calcium (CAC) and with
of CAC as compared with those without MA (open bars). In this un
CAC progression among those with versus those without MA persis
Table 4. Multivariable Analysis of Absolute Progression of Coro
Model 1
* (95% CI)
Volume CAC Scores
Overall (n  2,755) 15.01 (8.13–21.90)
Whites (n  1,256) 18.54 (5.84–31.23)
Chinese Americans (n  328) 16.46 (0.60–32.32)
African Americans (n  627) 17.75 (3.42–32.08)
Hispanics (n  544) 9.45 (5.31–24.20)
*Regression coefﬁcients are derived from median regression analysis. Model 1 a
for age, gender, race, MESA site, follow-up duration, body mass index, hype
triglycerides, and cholesterol-lowering medications. Race was not adjusted for
blood pressure as a continuous variable, creatinine, or estimated glomerular ﬁl
Abbreviations as in Tables 1, 2, and 3.emain significant even after adjustment for CHD
isk factors, and creatinine or estimated glomerular
ltration rate had no significant impact on the
esults. Among those with detectable coronary ath-
rosclerosis at baseline, by coronary calcium mea-
ures, the presence and degree of MA was associ-
ted with the degree of coronary atherosclerosis
rogression (coronary calcium) after taking into
ccount traditional CHD risk factors. Creatinine or
stimated glomerular filtration rate had no signifi-
ant impact on this relationship. No significant
nteraction between MA, as it relates to incident
AC and CAC progression, and ethnic groups was
ound. Only 1 race/MA interaction was detected
or an increased risk of incident CAC with log
ACR among Chinese as compared with Whites.
his may be due to smaller sample size within the
ubethnic groups. Further study will be needed to
etermine whether MA is a more sensitive and/or
inese
42
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Hispanic
28
36
Microalbuminuria (+)
ace/Ethnicity Among Those With CAC >0 at Baseline
eline microalbuminuria (MA) (solid bars) had greater progression
iant analysis, stratiﬁed by self-identiﬁed race, the trend of greater
Calcium With Presence of MA
Model 2
p Value
* (95% CI)
Volume CAC Scores p Value
0.0001 9.39 (2.30–16.48) 0.009
0.004 3.27 (12.19–18.74) 0.68
0.042 13.86 (3.92–31.56) 0.13
0.015 8.43 (6.31–23.17) 0.27
0.21 7.12 (5.33–19.57) 0.26
ted for age, gender, race, MESA site, and follow-up duration. Model 2 adjusted
sion, diabetes mellitus, cigarette smoking, family history of CHD, LDL, HDL,
speciﬁc analyses. Adjustment for type of scanner used to access CAC, systolic
n rate had no signiﬁcant impact on the results.Ch
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602pecific marker of the progression of atherosclerosis
mong any specific ethnic/racial group.
The mechanisms for the increased incidence and
ccelerated progression of coronary atherosclerosis
n the presence of MA are unclear. Several studies,
ncluding data from our study, have established MA
s an independent risk factor for cardiovascular
isease in prospective analyses (1–3,34). This inde-
endent relationship remains true with respect to
enal insufficiency, which in itself is a risk factor for
ardiovascular disease. This was most clearly dem-
nstrated in an analysis of over 14,000 individuals
ith over 13 years of follow-up in the NHANES
II (National Health and Nutrition Examination
urvey III) study, which established estimated glo-
erular filtration rate and MA to be independent
isk factors for cardiovascular disease events (34).
A may be the result of vascular damage to the
lomerulus. Although this damage to the kidney is
eflected as albumin in the urine, the process of
ascular damage resulting in atherosclerosis is likely
ngoing in all vascular beds, including the heart.
hus, MA may be a cumulative measure of the
mpact of multiple factors on vasculature health.
A has been shown to correlate with depressed
ascular function, including the coronary artery
asculature as measured by vasodilatory response to
arious stimuli (5,6).
In our study, MA preceded the detection of
therosclerosis by CAC in the majority of partici-
ants. A limitation of our study is that although
ACR is a dynamic measure impacted by multiple
actors, including antihypertensive medications,
nly a single UACR was used. It is not known
hether repetitive UACR measures would have
ead to an even larger proportion of MA preceding
AC detection. Speculation as to why MA pre-
edes CAC include the glomerulus may be more
Table 5. Multivariable Analysis of Absolute Progression of Coro
Model 1
* (95% CI)
Volume CAC Scores
Overall (n  2,755) 4.90 (2.92–6.89)
Whites (n  1,256) 4.49 (1.38–7.60)
Chinese Americans (n  328) 7.16 (1.66–12.65)
African Americans (n  627) 8.24 (3.68–12.80)
Hispanics (n  544) 3.49 (1.22–8.20)
*Regression coefﬁcients are derived from median regression analysis. Model 1 a
for age, gender, race, MESA site, follow-up duration, body mass index, hype
triglycerides, and cholesterol-lowering medications. Race was not adjusted for
blood pressure as a continuous variable, creatinine, or estimated glomerular ﬁl
Abbreviations as in Tables 1, 2, and 3.ensitive to vascular damage than the coronary Crteries, or MA may reflect the lag time between
he development of atherosclerosis and calcification
f arthrosclerotic plaque. It is also possible that MA
s a more sensitive measure of atherosclerotic dam-
ge in the glomerulus than detection of calcification
y computerized tomography in the coronary arter-
es. Regardless, these findings support the notion
hat MA is an early measure of systemic vascular
ealth/damage. It is important to note that we have
sed CAC progression as a measure of atheroscle-
osis progression in our study. Although extensive
nd robust data exist on the prognostic value of
AC severity in predicting adverse cardiovascular
utcome, less data exist as to whether CAC pro-
ression may provide additional information re-
arding the heightened risk of future events. A
tudy of 495 asymptomatic patients with baseline
AC examined the impact of CAC progression at
years on incident myocardial infarctions (19).
rogression of coronary artery calcium on the
ollow-up scan was associated with a 17-fold in-
reased relative risk (p  0.0001) of a myocardial
nfarction as compared with those without progres-
ion of coronary calcium. Further studies are needed
o more clearly delineate the role of CAC progres-
ion in risk prediction and evaluation of treatment
fficacy. In addition, it is also yet to be seen among
articipants with MA whether a differential out-
ome will exist according to the severity of CAC
rogression.
Our study findings raise 3 important questions.
irst, should we assess the presence of MA in all
symptomatic patients? Given that the association
etween MA and increased cardiovascular (CV)
isk is well established, and the reduction in urine
lbumin excretion at 1 year was associated with a
eduction in CV risk in 1 study, screening for MA
o help identify patients that are at increased risk for
Calcium With Increasing Levels of UACR (Log-Transformed)
Model 2
p Value
* (95% CI)
Volume CAC Scores p Value
0.0001 3.06 (0.77–5.35) 0.009
0.005 1.19 (3.75–6.13) 0.64
0.011 4.09 (2.98–11.15) 0.26
0.019 4.70 (0.46–8.94) 0.03
0.15 1.68 (2.44–5.80) 0.42
ted for age, gender, race, MESA site, and follow-up duration. Model 2 adjusted
sion, diabetes mellitus, cigarette smoking, family history of CHD, LDL, HDL,
speciﬁc analyses. Adjustment for type of scanner used to access CAC, systolic
n rate had no signiﬁcant impact on the results.nary
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603herapeutic change (prescribing aspirin, statin,
ngiotensin-converting enzyme inhibitor). It
hould be noted that currently, no professional
ociety guidelines exist for MA screening to identify
ndividuals at increased CV risk. Second, can we use
A to select which patients should undergo CAC
esting? Currently, an American Heart Association
cientific statement gives a tepid endorsement (class
Ib, Level of Evidence: B) for CAC testing in
ntermediate-risk patients, to refine clinical risk
rediction, and to select patients for more aggres-
ive target values for lipid-lowering therapies (35).
he presence or absence of MA can potentially aid
n the decision to proceed or forgo CAC testing
ased on the threshold for treatment in an individ-
al patient. The third question our study finding
oses is can we use MA to determine which
atients on whom we should perform follow-up
AC testing in the future? Although in our large,
opulation-based study we demonstrate an associ-
tion between MA and CAC progression, we
elieve additional data confirming these findingsAttali JR, Nitenberg A. Impaired cor-
onary endothelium-dependent vaso- 2004;291:210–5.rogression of clinical outcomes are needed before
linical utility recommendations can be made about
A testing and sequential CAC testing.
In summary, this large, population-based study
emonstrates an increased risk of incident CAC
s well as greater CAC progression among those
ith MA. Further study is needed to determine
he degree to which MA precedes and predicts
rogression of atherosclerosis and how this infor-
ation can be used to reduce cardiovascular
vents.
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